华东医药(000963.SZ)：注射用HDM2017药品临床试验申请已获得美国FDA批准

Core Viewpoint - Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong"), has received notification from the U.S. Food and Drug Administration (FDA) that the clinical trial application for the injectable HDM2017 drug submitted by Zhongmei Huadong has been approved, allowing the company to conduct Phase I clinical trials in the U.S. for the indication of advanced malignant solid tumors [1]. Company Summary - Huadong Medicine's subsidiary, Zhongmei Huadong, has received FDA approval for its clinical trial application [1]. - The approved drug, HDM2017, is intended for the treatment of advanced malignant solid tumors [1].